David Charles Lubner Purchases 55,555 Shares of Braveheart Bio (NASDAQ:BRVE) Stock

Braveheart Bio, Inc. (NASDAQ:BRVE) Director David Charles Lubner bought 55,555 shares of the stock in a transaction on Friday, August 7th. The shares were bought at an average price of $18.00 per share, with a total value of $999,990.00. Following the acquisition, the director owned 55,555 shares of the company’s stock, valued at $999,990. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Braveheart Bio Trading Up 0.7%

Shares of NASDAQ:BRVE traded up $0.20 on Friday, reaching $30.00. The company had a trading volume of 565,846 shares. Braveheart Bio, Inc. has a 52-week low of $28.47 and a 52-week high of $32.00.

About Braveheart Bio

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.